Seuraa
Peter A. Fasching
Peter A. Fasching
Friedrich-Alexander University
Vahvistettu sähköpostiosoite verkkotunnuksessa uk-erlangen.de - Kotisivu
Nimike
Viittaukset
Viittaukset
Vuosi
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
P Cortazar, L Zhang, M Untch, K Mehta, JP Costantino, N Wolmark, ...
The Lancet 384 (9938), 164-172, 2014
31852014
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
G Von Minckwitz, M Untch, JU Blohmer, SD Costa, H Eidtmann, ...
J Clin oncol 30 (15), 1796-1804, 2012
22862012
Trastuzumab emtansine for residual invasive HER2-positive breast cancer
G Von Minckwitz, CS Huang, MS Mano, S Loibl, EP Mamounas, M Untch, ...
New England Journal of Medicine 380 (7), 617-628, 2019
12892019
Large-scale genotyping identifies 41 new loci associated with breast cancer risk
K Michailidou, P Hall, A Gonzalez-Neira, M Ghoussaini, J Dennis, ...
Nature genetics 45 (4), 353-361, 2013
11722013
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
C Denkert, G von Minckwitz, S Darb-Esfahani, B Lederer, BI Heppner, ...
The lancet oncology 19 (1), 40-50, 2018
10312018
Association analysis identifies 65 new breast cancer risk loci
K Michailidou, S Lindström, J Dennis, J Beesley, S Hui, S Kar, A Lemaçon, ...
Nature 551 (7678), 92-94, 2017
9552017
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies
CL Pearce, C Templeman, MA Rossing, A Lee, AM Near, PM Webb, ...
The lancet oncology 13 (4), 385-394, 2012
9242012
Pembrolizumab for early triple-negative breast cancer
P Schmid, J Cortes, L Pusztai, H McArthur, S Kümmel, J Bergh, C Denkert, ...
New England Journal of Medicine 382 (9), 810-821, 2020
9102020
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
G Von Minckwitz, A Schneeweiss, S Loibl, C Salat, C Denkert, M Rezai, ...
The lancet oncology 15 (7), 747-756, 2014
8922014
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies
XR Yang, J Chang-Claude, EL Goode, FJ Couch, H Nevanlinna, RL Milne, ...
Journal of the National Cancer Institute 103 (3), 250-263, 2011
7672011
Phase III randomized study of ribociclib and fulvestrant in hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: MONALEESA-3
DJ Slamon, P Neven, S Chia, PA Fasching, M De Laurentiis, SA Im, ...
Journal of Clinical Oncology 36 (24), 2465-2472, 2018
6342018
Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer
FJ Couch, SN Hart, P Sharma, AE Toland, X Wang, P Miron, JE Olson, ...
Journal of clinical oncology 33 (4), 304, 2015
6312015
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study
M Untch, M Rezai, S Loibl, PA Fasching, J Huober, H Tesch, I Bauerfeind, ...
Journal of Clinical Oncology 28 (12), 2024-2031, 2010
6042010
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer
SE Bojesen, KA Pooley, SE Johnatty, J Beesley, K Michailidou, JP Tyrer, ...
Nature genetics 45 (4), 371-384, 2013
5982013
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen
W Schroth, MP Goetz, U Hamann, PA Fasching, M Schmidt, S Winter, ...
Jama 302 (13), 1429-1436, 2009
5922009
Circulating tumor cells predict survival in early average-to-high risk breast cancer patients
B Rack, C Schindlbeck, J Jückstock, U Andergassen, P Hepp, T Zwingers, ...
Journal of the National Cancer Institute 106 (5), dju066, 2014
5782014
Polygenic risk scores for prediction of breast cancer and breast cancer subtypes
N Mavaddat, K Michailidou, J Dennis, M Lush, L Fachal, A Lee, JP Tyrer, ...
The American Journal of Human Genetics 104 (1), 21-34, 2019
5672019
Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer
K Michailidou, J Beesley, S Lindstrom, S Canisius, J Dennis, MJ Lush, ...
Nature genetics 47 (4), 373-380, 2015
5602015
Prediction of breast cancer risk based on profiling with common genetic variants
N Mavaddat, PDP Pharoah, K Michailidou, J Tyrer, MN Brook, MK Bolla, ...
JNCI: Journal of the National Cancer Institute 107 (5), 2015
5532015
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer
G von Minckwitz, H Eidtmann, M Rezai, PA Fasching, H Tesch, ...
New England Journal of Medicine 366 (4), 299-309, 2012
5432012
Järjestelmä ei voi suorittaa toimenpidettä nyt. Yritä myöhemmin uudelleen.
Artikkelit 1–20